NCT06479434View on ClinicalTrials.gov

Serum Biomarker Levels Improvement in Poly Cystic Ovarian Syndrome: Impact of Metformin Compared to Healthy Controls

NACompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

October 2, 2025

Conditions

Polycystic Ovary SyndromeInsulin Resistance

Interventions

DRUG

Metformin

Females diagnosed with polycystic syndrome will be given metformin tablets for 8 weeks and followed up. Blood samples will be collected along with anthropometric data (weight (kg), height (m) etc)

Trial Locations (1)

74800

DBBS, Karachi

All Listed Sponsors

collaborator

University of Karachi

OTHER

lead

Aga Khan University

OTHER

NCT06479434 - Serum Biomarker Levels Improvement in Poly Cystic Ovarian Syndrome: Impact of Metformin Compared to Healthy Controls | Biotech Hunter | Biotech Hunter